Treace Medical Concepts, Inc. (TMCI)

Market Cap	267.94M -29.3%
Revenue (ttm)	205.31M -4.0%
Net Income	-59.52M
EPS	-0.93
Shares Out	65.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	261,904
Open	4.040
Previous Close	4.040
Day's Range	4.040 - 4.210
52-Week Range	1.170 - 7.080
Beta	1.49
Analysts	Hold
Price Target	5.50 (+33.5%)
Est. Earnings	Nov 5, 2026

About TMCI

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percupla...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 23, 2021
• Employees: 450
• Stock Exchange: Nasdaq
• Ticker Symbol: TMCI
• Website: https://www.treace.com

Financial Performance

In 2025, Treace Medical Concepts's revenue was $212.69 million, an increase of 1.59% compared to the previous year's $209.36 million. Losses were -$59.00 million, 5.85% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for TMCI stock is "Hold." The 12-month stock price target is $5.5, which is an increase of 33.50% from the latest price.

Price Target

$5.5

(33.50% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error